Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: MMP value

Milestone: "I am surprised that no one has yet commented on how the alleged self-serving BoD has singularly failed to grant themselves current in-the-money options."

Perhaps they have but feel it would serve no purpose to issue a PR statement. For once, I agree.

Maybe the quarterly statement will reveal more - even though it will probably be later than usual given the apparent change in filing status Was there ever a formal announcement on that, or was it just buried in the reaction to the SEC action? I remember them alluding to 'negotiating' the change, but no categorical statement that the change was agreed.

I'm still very intrigued by "60 days from August 12th" to execrise all those options - unless they voted to extend the deadline.


Share
New Message
Please login to post a reply